Lupin launches Turqoz (Norgestrel and Ethinyl Estradiol) Tablets in US
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
The product is expected to be launched in FY25
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The Product will be manufactured at the company's facility in Bengaluru
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) and is used in the treatment of seizures.
Subscribe To Our Newsletter & Stay Updated